37 published articles · Updated continuously
10 trials tracked for Hypersensitivity, Immediate: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 128 citations.
Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Dupilumab demonstrated significant efficacy in improving skin symptoms for patients with hypersensitivity. At week 16, a high percentage of participants achieved an Investigator's Global Assessment (IGA) score of 0 or 1 with a reduction of at least 2 points compared to baseline 1. Additionally, treatment resulted in a significant reduction in Eczema Area and Severity Index (EASI) scores by approximately 64.8% to 65.9% at week 16 1.
PF-04965842 100 mg showed clinical efficacy in improving skin conditions and reducing pruritus. At week 12, a significant percentage of patients achieved an IGA response of clear or almost clear (0 or 1) with at least a 2-point reduction from baseline 3. Furthermore, there was a statistically significant improvement in the Numerical Rating Scale (NRS) for the severity of pruritus across multiple time points up to week 16 3.
Evidence regarding the durability of response for PF-04965842 100 mg indicates that treatment significantly extended the time to loss of response compared to placebo. The median time to first loss of response (IGA score of 2 or higher) was notably longer in the treatment group 2.
AI synthesis of 8 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
